New, complex therapies coming through the pharma pipelines are putting immense pressure on supply chains and manufacturing capacity, challenging traditional scale-up and manufacturing processes at the same time — and CDMOs have stepped up into the thick of it all.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.